Hypertonic Saline in Infants and Young Children with Cystic Fibrosis (Pilot)
Restore Airway Surface Liquid
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
This study assessed the safety of Hypertonic Saline (HS) infants and young children with CF. This study compared lung function before and after different strengths of HS in children between the ages of 4 and 7 years. Also, oxygen levels, breathing rate, physical exam changes and a cough record before and after administration of HS were recorded. In infants lung function before and after HS was compared.
1 Months - 8 Years
>= 60 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The abstract presents the preliminary results on the initial 6 patients enrolled in the study and concluded that a single administration of 3% saline was well-tolerated in children age 4 months to 4 years.
The summary of data provided here is from an abstract presented at the Cystic Fibrosis Foundation North American CF Conference (2007). These data may be preliminary and have not been peer-reviewed.